BAX and BAK are pro-apoptotic BCL-2 family proteins that function as the essential gatekeepers of mitochondrial apoptosis. In response to cellular stress, BAX and BAK transform from inactive monomers into toxic, homo-oligomeric pores that pierce the mitochondrial membrane, releasing apoptogenic factors that drive the death pathway. Anti-apoptotic proteins, such as BCL-2, block cell death by trapping the critical death effector helix, termed BH3, of BAX and BAK in a surface groove. The BH3-only subgroup of BCL-2 proteins only share a conserved BH3 domain, which is deployed to transmit stress signals to anti- and pro-apoptotic targets. Whereas BH3-only proteins can bind the anti-apoptotic groove to derepress activated conformers of BAX and BAK (indirect activation), select members can also directly trigger BAX and BAK (direct activation). The structural and biochemical basis for the direct activation mechanism was long unknown. In the current award period, we demonstrated that chemically-reinforced BH3 helices of the activator BH3-only proteins BIM, BID, and PUMA bound to a novel trigger site on the N-terminal face of BAX, directly activating BAX-mediated mitochondrial membrane poration and cellular apoptosis. This work revealed a new interaction paradigm for BCL-2 family proteins, and has formed the basis for designing prototype therapeutics to reactivate apoptosis in cancer through direct BAX engagement. Facilitated by our development of a recombinant form of full-length BAK and a photoaffinity labeling/mass spectrometry method for rapid binding-site identification, we recently identified functional BH3 interaction sites at the C-terminal faces of BAK and BAX. We hypothesize that these C-terminal sites propel BAX and BAK activation at the mitochondrial membrane. Thus, we now propose to develop specific probes for the three BH3 trigger sites to systematically dissect the structural, biochemical, and functional consequences of direct and selective BAX/BAK activation. Specifically, we aim to (1) dissect the binding and specificity determinants for direct engagement of the BH3 trigger sites of pro-apoptotic BAX and BAK, (2) functionally link the selective BAX and BAK binding activity of BH3 helices with direct activation of BAX/BAK-mediated membrane poration in vitro and in cells, and (3) define the conformational changes along the direct BAX and BAK activation pathways by hydrogen-deuterium exchange mass spectrometry (HXMS). By complementing our biochemical and functional studies with structural determination of the three BH3/trigger site complexes, we aim to provide new blueprints for the development of pharmacologic activators of apoptosis through direct BAX and BAK triggering. We will also apply HXMS to accomplish the first BAX/BAK-in-motion study of its kind, designed to unveil the continuum of structural changes from monomer to oligomer in real time and in the physiologic membrane environment. In combining chemistry, biochemistry, structural biology, mass spectrometry, and apoptosis biology, we remain laser-focused on elucidating the fundamental protein interaction mechanisms harnessed by BAX and BAK to execute mitochondrial apoptosis.

Public Health Relevance

BCL-2 family proteins regulate programmed cell death, or apoptosis, a critical pathway that controls the balance between new and dying cells during health and disease. Whereas cancer cells overexpress BCL-2 family survival proteins to achieve an immortal state, the structural and biochemical dissection of this pathologic mechanism has informed the development of new cancer therapeutics that inhibit the inhibitors of cell death. Here, we harness multidisciplinary approaches to elucidate the fundamental protein interaction mechanisms and conformational transformations employed by BAX and BAK, the pro-apoptotic effectors of the BCL-2 family, to kill cells, and thereby advance an activate the activators paradigm for apoptosis induction and cancer drug design.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Cellular Signaling and Regulatory Systems Study Section (CSRS)
Program Officer
Salnikow, Konstantin
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Dana-Farber Cancer Institute
United States
Zip Code
Bird, Greg H; Gavathiotis, Evripidis; LaBelle, James L et al. (2014) Distinct BimBH3 (BimSAHB) stapled peptides for structural and cellular studies. ACS Chem Biol 9:831-7
Lee, Susan; Braun, Craig R; Bird, Gregory H et al. (2014) Photoreactive stapled peptides to identify and characterize BCL-2 family interaction sites by mass spectrometry. Methods Enzymol 544:25-48
Walensky, Loren D; Bird, Gregory H (2014) Hydrocarbon-stapled peptides: principles, practice, and progress. J Med Chem 57:6275-88
Edwards, Amanda L; Gavathiotis, Evripidis; LaBelle, James L et al. (2013) Multimodal interaction with BCL-2 family proteins underlies the proapoptotic activity of PUMA BH3. Chem Biol 20:888-902
Katz, S G; Fisher, J K; Correll, M et al. (2013) Brain and testicular tumors in mice with progenitor cells lacking BAX and BAK. Oncogene 32:4078-85
Hilgendorf, Keren I; Leshchiner, Elizaveta S; Nedelcu, Simona et al. (2013) The retinoblastoma protein induces apoptosis directly at the mitochondria. Genes Dev 27:1003-15
Walensky, Loren D (2013) Protein-protein interactions: A PUMA mechanism unfolds. Nat Chem Biol 9:141-3
Walensky, Loren D (2013) Direct BAKtivation. Nat Struct Mol Biol 20:536-8
Leshchiner, Elizaveta S; Braun, Craig R; Bird, Gregory H et al. (2013) Direct activation of full-length proapoptotic BAK. Proc Natl Acad Sci U S A 110:E986-95
Walensky, Loren D; Gavathiotis, Evripidis (2011) BAX unleashed: the biochemical transformation of an inactive cytosolic monomer into a toxic mitochondrial pore. Trends Biochem Sci 36:642-52

Showing the most recent 10 out of 39 publications